SCHEMBL592676

SCHEMBL592676

CNc1ccc(OC(CC(C)C)[C@H]2CCN(C(=O)OC(C)(C)C)C2)c(C)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 9/20 0.41
▸ SLC6A2 P23975 5/20 0.40
▸ SLC6A4 P31645 5/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ TRPV3 Q8NET8 1/20 0.38
▸ MAPT P10636 3/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL590425 0.87 SLC6A2 (0.41) GPR119SLC6A2SLC6A4SLC6A3TRPV3
SCHEMBL10090874 0.87 SLC6A2 (0.41) GPR119SLC6A2SLC6A4SLC6A3TRPV3
SCHEMBL590981 0.86 SLC6A2 (0.55) GPR119SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL586621 0.86 SLC6A2 (0.45) GPR119SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL2675436 0.83 GPR119 (0.45) GPR119
SCHEMBL586400 0.76 SSTR4 (0.40) GPR119MAPTNPSR1ALDH1A1MAPK1
SCHEMBL2676756 0.75 SSTR4 (0.39) GPR119TRPV3NPSR1ALDH1A1MEN1
SCHEMBL2675452 0.75 GPR119 (0.41) GPR119POLBUSP30
SCHEMBL10090887 0.74 SLC6A2 (0.40) GPR119SLC6A2SLC6A4SLC6A3MAPT
SCHEMBL2676342 0.74 USP30 (0.42) GPR119MAPTNPSR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2417124-B1 Serotonin and norepinephrine reuptake inhibitor LILLY CO ELI (US) 2013-12-18 — — EP disclosed
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
EP-2417124-A2 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR Eli Lilly and Company (US) 2012-02-15 — — EP disclosed
WO-2010117979-A2 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — WO disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR SLC6A2, SLC6A4, TPH1 GPR119 708/4885SLC6A2 1/4885SLC6A4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback